Antibody Discovery Services and Platforms Market (5th Edition): Distribution by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, Lead Characterization), Antibody Discovery Method (Hybridoma based, Library based, Single Cell based, Transgenic Animal based), Type of Antibody Generated (Monoclonal Antibodies, Bispecific Antibodies and Others), Nature of Antibody Generated (Chimeric, Human, Humanized and Murine), Type of Therapeutic Areas (Cardiovascular Disorders, Immunological Disorders, Infectious Disorders, Neurological Disorders, Oncological Disorders and Others) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2023-2035
The global antibody discovery services and platforms market is expected to reach USD 1.6 billion by 2023 anticipated to grow at a CAGR of 12% during the forecast period 2023-2035.
Developing drugs, from discovery to market, usually spans 10-15 years and involves substantial investments, often exceeding $2 billion. Unfortunately, more than 90% of drug candidates don't pass clinical trials. To streamline this process, reduce timelines, and manage the risk, pharmaceutical companies are outsourcing aspects of their discovery work to specialized contract research organizations (CROs). Collaborating with antibody CROs helps companies in the antibody discovery market optimize resources, cut costs, and tap into a global scientific talent pool, enhancing efficiency and success rates in bringing new antibody-based therapies to market.
Monoclonal antibody-based therapies, like Orthoclone OKT3® approved in 1986, have advanced significantly. They've diversified in formats, undergone engineering improvements, and benefited from innovative discovery methods. Over 160 monoclonal antibodies have been approved for various diseases, including cancer, chronic inflammatory conditions, infectious diseases, and cardiovascular ailments. Recently, therapies like ELREXFIO™, TALVEY™, Rystiggo®, COLUMVI®, and EPKINLY™ were approved between May 2023 and August 2023. Due to the complexity of discovering these antibodies, many companies choose to license specialized antibody discovery platforms and technologies. The growing demand for antibody-based therapies and the preference for outsourcing indicate a significant expected expansion in antibody discovery services and platforms in the future.
Report Coverage
Developing drugs, from discovery to market, usually spans 10-15 years and involves substantial investments, often exceeding $2 billion. Unfortunately, more than 90% of drug candidates don't pass clinical trials. To streamline this process, reduce timelines, and manage the risk, pharmaceutical companies are outsourcing aspects of their discovery work to specialized contract research organizations (CROs). Collaborating with antibody CROs helps companies in the antibody discovery market optimize resources, cut costs, and tap into a global scientific talent pool, enhancing efficiency and success rates in bringing new antibody-based therapies to market.
Monoclonal antibody-based therapies, like Orthoclone OKT3® approved in 1986, have advanced significantly. They've diversified in formats, undergone engineering improvements, and benefited from innovative discovery methods. Over 160 monoclonal antibodies have been approved for various diseases, including cancer, chronic inflammatory conditions, infectious diseases, and cardiovascular ailments. Recently, therapies like ELREXFIO™, TALVEY™, Rystiggo®, COLUMVI®, and EPKINLY™ were approved between May 2023 and August 2023. Due to the complexity of discovering these antibodies, many companies choose to license specialized antibody discovery platforms and technologies. The growing demand for antibody-based therapies and the preference for outsourcing indicate a significant expected expansion in antibody discovery services and platforms in the future.
Report Coverage
- The report extensively examines the antibody discovery market, categorizing it by service type, discovery method, antibody type, nature, therapeutic fields, and key geographical regions.
- It thoroughly analyzes market growth influencers such as drivers, restraints, opportunities, and challenges.
- The report evaluates both advantages and obstacles within the market landscape and offers insights into the competitive environment among top market players.
- Revenue forecasts for market segments are provided across six major regions.
- Detailed insights into the systematic research approach, methodologies, assumptions, and quality control measures employed ensure the accuracy and reliability of findings.
- Analysis encompasses historical trends, currency fluctuations, foreign exchange impacts, recession effects, and inflation measurements affecting antibody discovery services and platforms.
- It provides a concise overview of the present market status and forecasts the short, mid, and long-term evolution of the antibody discovery services and platforms market.
- Comprehensive coverage of historical context, structural details, isotypes, mechanisms of action, and applications of antibodies, with emphasis on monoclonal, bispecific, and polyclonal types.
- Detailed examination and comparison of discovery methods, tracking the developmental trends of monoclonal antibodies from murine to human variants over the past three decades.
- Analysis of over 160 active service providers based on various parameters such as establishment year, company size, location, services offered, discovery methods, animal models used, types of antibodies, and purposes.
- Comparative evaluation of companies based on experience, platforms, services offered, discovery methods, antibody formats, application areas, and regional capabilities.
- In-depth profiles of companies providing antibody discovery services, including company overview, recent developments, and future outlook.
- Examination of 290+ platforms based on antibody types, discovery methods, animal models, establishment year, company size, and headquarters location.
- Assessment of leading market players considering supplier power, platform specifications, antibody compatibility, and deals signed between 2015-2023.
- Detailed information about companies offering access/licenses to their antibody discovery platforms or technologies, including company overview, platform details, recent developments, and future outlook.
- Evaluation of partnerships established within the antibody discovery market from 2021-2023, with descriptions of partnership models adopted by stakeholders.
- Examination of investments in the antibody discovery market from 2016-2023 across various financing stages and sources.
- Insights into cash flows, net present values, and scenarios of upfront, milestone, and royalty payments between licensors and licensees.
- Detailed discussion on industry-specific trends, market drivers, challenges, key players, and influencing factors in antibody humanization services.
- Presentation of detailed profiles of top-selling drugs in 2022, including historical sales, discovery processes, and methods.
- Discussion on upcoming antibody therapeutics and technologies expected to impact the industry's evolution in the coming decade.
- Ablexis
- Antibody Solutions
- ChemPartner
- Creative Biolabs
- GenScript
- Genmab
- Harbour BioMed
- ImmunoPrecise
- MabSilico
- Myrio Therapeutics
- Nona Biosciences
- Rockland Immunochemicals
- Synbio technologies
- WuXi Biologics
1. PREFACE
1.1. Introduction
1.2. Project Objectives
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Considerations
2.6.1. Demographics
2.6.2. Economic Factors
2.6.3. Government Regulations
2.6.4. Supply Chain
2.6.5. COVID Impact / Related Factors
2.6.6. Market Access
2.6.7. Healthcare Policies
2.6.8. Industry Consolidation
2.7. Key Market Segmentation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Trends Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Structure of Antibodies
5.3. History of Antibody Development
5.4. Antibody Isotypes
5.5. Mechanism of Action of Antibodies
5.6. Classification of Antibodies
5.6.1. Monoclonal Antibodies
5.6.2. Polyclonal Antibodies
5.6.3. Bispecific Antibodies
5.7. Applications of Antibodies
5.8. Concluding Remarks
6. ANTIBODY DISCOVERY: PROCESS AND METHODS
6.1. Chapter Overview
6.2. Antibody Discovery Process
6.2.1. Target Selection and Validation
6.2.2. Hit Generation
6.2.3. Lead Selection
6.2.4. Lead Optimization
6.2.4.1. Humanization
6.2.4.2. Affinity Maturation
6.2.4.3. Fc Engineering
6.2.5. Lead Characterization
6.2.6. Candidate Selection
6.3. Antibody Discovery Methods
6.3.1. Hybridoma Technology-based Method
6.3.2. In vitro Display Method
6.3.2.1. Phage Display
6.3.2.2. Yeast Display
6.3.2.3. Ribosomal Display
6.3.3. Transgenic Animal-based Method
6.3.4. Single B Cell-based Method
6.3.5. Advantages and Disadvantages of Existing Antibody Discovery Techniques
6.4. Evolution of Monoclonal Antibodies
6.4.1. Fully Human Monoclonal Antibodies
6.5. Concluding Remarks
7. ANTIBODY DISCOVERY SERVICE PROVIDERS: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers: List of Industry Players
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Type of Antibody Discovery Services Offered
7.2.5. Analysis by Type of Antibody Discovered
7.2.6. Analysis by Type of Antibody Discovery Method
7.2.7. Analysis by Animal Model Used
7.2.8. Analysis by Type of Antibody Discovered and Type of Antibody Discovery Method
7.2.9. Analysis by Type of Antibody Discovery Services and Location of Headquarters
7.2.10. Analysis by Application Area
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Competitiveness Analysis: Companies Grouped Grouped based on Company Size
8.4.1. Very Small Companies Offering Antibody Discovery Services
8.4.2. Small Companies Offering Antibody Discovery Services
8.4.3. Mid-sized Companies Offering Antibody Discovery Services
8.4.4. Large Companies Offering Antibody Discovery Services
8.5. Antibody Discovery Service Providers: Regional Capability
8.5.1. Antibody Discovery Service Providers based in North America
8.5.2. Antibody Discovery Service Providers based in Europe
8.5.3. Antibody Discovery Service Providers based in Asia
9. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
9.1. Chapter Overview
9.2. Antibody Discovery Service Providers in North America
9.2.1. Abwiz Bio
9.2.1.1. Company Overview
9.2.1.2. Recent Developments and Future Outlook
9.2.2. Abzena
9.2.2.1. Company Overview
9.2.2.2. Recent Developments and Future Outlook
9.2.3. Aragen Life Sciences
9.2.3.1. Company Overview
9.2.3.2. Recent Developments and Future Outlook
9.2.4. Capralogics
9.2.4.1. Company Overview
9.2.4.2. Recent Developments and Future Outlook
9.2.5. Creative Biolabs
9.2.5.1. Company Overview
9.2.5.2. Financial Information
9.2.5.3. Recent Developments and Future Outlook
9.2.6. DetaiBio
9.2.6.1. Company Overview
9.2.6.2. Recent Developments and Future Outlook
9.2.7. ImmunoPrecise Antibodies
9.2.7.1. Company Overview
9.2.7.2. Financial Information
9.2.7.3. Recent Developments and Future Outlook
9.2.8. Integral Molecular
9.2.8.1. Company Overview
9.2.8.2. Recent Developments and Future Outlook
9.2.9. Syd Labs
9.2.9.1. Company Overview
9.2.9.2. Recent Developments and Future Outlook
9.3. Antibody Discovery Service Providers in Europe
9.3.1. BIOTEM
9.3.1.1. Company Overview
9.3.1.2. Recent Developments and Future Outlook
9.3.2. FairJourney Biologics
9.3.2.1. Company Overview
9.3.2.2. Recent Developments and Future Outlook
9.3.3. Fusion Antibodies
9.3.3.1. Company Overview
9.3.3.2. Recent Developments and Future Outlook
9.3.4. Proteogenix
9.3.4.1. Company Overview
9.3.4.2. Recent Developments and Future Outlook
9.3.5. RD Biotech
9.3.5.1. Company Overview
9.3.5.2. Recent Developments and Future Outlook
9.4. Antibody Discovery Service Providers in Asia
9.4.1. ABGENEX
9.4.1.1. Company Overview
9.4.1.2. Recent Developments and Future Outlook
9.4.2. ChemPartner
9.4.2.1. Company Overview
9.4.2.2. Recent Developments and Future Outlook
9.4.3. Viva Biotech
9.4.3.1. Company Overview
9.4.3.2. Financial Information
9.4.3.3. Recent Developments and Future Outlook
9.4.4. WuXi Biologics
9.4.4.1. Company Overview
9.4.4.2. Financial Information
9.4.4.3. Recent Developments and Future Outlook
10. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET LANDSCAPE
10.1. Chapter Overview
10.2. Antibody Discovery: List of Technologies
10.2.1. Analysis by Type of Antibody Discovery Method
10.2.2. Analysis by Type of Antibody Discovered
10.2.3. Analysis by Animal Model Used
10.2.4. Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered
10.2.5. Analysis by Type of Antibody Discovery Method and Location of Headquarters
10.3. Antibody Discovery Technologies: Developer Landscape
10.3.1. Analysis by Year of Establishment
10.3.2. Analysis by Company Size
10.3.3. Analysis by Location of Headquarters
10.3.4. Most Active Players: Analysis by Number of Technologies
11. TECHNOLOGY COMPETITIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology
11.4. Antibody Discovery Technologies: Competitiveness Analysis
11.4.1. Antibody Discovery Technologies Offered by Companies based in North America
11.4.2. Antibody Discovery Technologies Offered by Companies based in Europe
11.4.3. Antibody Discovery Technologies Offered by Companies based in Asia and Rest of the World
12. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
12.1. Chapter Overview
12.2. Ablexis
12.2.1. Company Overview
12.2.2. Antibody Discovery Platform Portfolio
12.2.3. Recent Developments and Future Outlook
12.3. Creative Biolabs
12.3.1. Company Overview
12.3.2. Antibody Discovery Platform Portfolio
12.3.3. Recent Developments and Future Outlook
12.4. Genmab
12.4.1. Company Overview
12.4.2. Financial Information
12.4.3. Antibody Discovery Platform Portfolio
12.4.4. Recent Developments and Future Outlook
12.5. Harbour Biomed
12.5.1. Company Overview
12.5.2. Financial Information
12.5.3. Antibody Discovery Platform Portfolio
12.5.4. Recent Developments and Future Outlook
12.6. Immunome
12.6.1. Company Overview
12.6.2. Antibody Discovery Platform Portfolio
12.6.3. Recent Developments and Future Outlook
12.7. Isogenica
12.7.1. Company Overview
12.7.2. Antibody Discovery Platform Portfolio
12.7.3. Recent Developments and Future Outlook
12.8. Ligand Pharmaceuticals
12.8.1. Company Overview
12.8.2. Financial Information
12.8.3. Antibody Discovery Platform Portfolio
12.8.4. Recent Developments and Future Outlook
12.9. Kymab
12.9.1. Company Overview
12.9.2. Antibody Discovery Platform Portfolio
12.9.3. Recent Developments and Future Outlook
12.10. MorphoSys
12.10.1. Company Overview
12.10.2. Financial Information
12.10.3. Antibody Discovery Platform Portfolio
12.10.4. Recent Developments and Future Outlook
13. PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models
13.3. List of Partnerships and Collaborations
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Year of Partnership and Type of Partner
13.3.4. Analysis by Type of Antibody
13.3.5. Most Active Players: Analysis by Number of Partnerships
13.3.6. Most Popular Technologies: Analysis by Number of Partnerships
13.3.7. Analysis by Geography
13.3.8. Intracontinental and Intercontinental Agreements
14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. Antibody Discovery Service and Platform Providers: Funding and Investment
14.3.1. Analysis by Year of Funding
14.3.2. Analysis by Type of Funding
14.3.3. Analysis of Amount Invested by Year of Funding
14.3.4. Analysis by Year-wise Number of Funding Instances and Funding Amount
14.3.5. Most Active Players: Analysis by Number of Funding Instances
14.3.6. Most Active Players: Analysis by Amount Invested
14.3.7. Leading Investors: Analysis by Number of Funding Instances
14.3.8. Analysis by Year-wise Number of Funding Instances and Type of Player
14.3.9. Analysis by Year-wise Amount Invested and Type of Player
14.3.10. Analysis of Number of Funding Instances by Year of Establishment and Type of Player
14.3.11. Analysis by Geography
14.4. Concluding Remarks
15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
15.1. Chapter Overview
15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges
15.6. Conclusion
16. GLOBAL ANTIBODY DISCOVERY SERVICES MARKET
16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Global Antibody Discovery Services Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
16.3.1. Scenario Analysis
16.4. Key Market Segmentations
16..5. DYNAMIC DASHBOARD
17. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF SERVICE OFFERED
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Antigen Designing: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.4. Hit Generation: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.5. Lead Selection: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.6. Lead Optimization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.7. Lead Characterization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.8. Data Triangulation and Validation
18. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF ANTIBODY DISCOVERY METHOD
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Phage Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.4. Yeast Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.5. Hybridoma Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.6. Transgenic Animal based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.7. Single Cell based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.8. Other Antibody Discovery Methods: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.9. Data Triangulation and Validation
19. ANTIBODY DISCOVERY SERVICES MARKET, BY NATURE OF ANTIBODY DISCOVERED
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Humanized: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.4. Human: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.5. Chimeric: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.6. Murine: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.7. Data Triangulation and Validation
20. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF THERAPEUTIC AREAS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Oncological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.4. Immunological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.5. Infectious Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.6. Neurological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.7. Cardiovascular Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.8. Other Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.9. Data Triangulation and Validation
21. ANTIBODY DISCOVERY SERVICES MARKET, BY KEY GEOGRAPHIES
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.6. Latin America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.7. Middle East and North Africa: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.8. Rest of the World: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.9. Data Triangulation and Validation
22. GLOBAL ANTIBODY DISCOVERY TECHNOLOGIES MARKET
22.1. Chapter Overview
22.2. Assumptions and Methodology
22.3. Global Antibody Discovery Technologies Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
22.3.1. Scenario Analysis
22.4. Key Market Segmentations
22.5. Dynamic Dashboard
23. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY TYPE OF ANTIBODY DISCOVERED
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Monoclonal Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.4. Bispecific Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.5. Other Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.6. Data Triangulation and Validation
24. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY KEY GEOGRAPHIES
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.6. Data Triangulation and Validation
25. LICENSING DEAL STRUCTURE
25.1. Chapter Overview
25.2. Key Parameters
25.3. Assumptions and Methodology
25.3.1. Overall Cash Flow for Licensee Companies
25.3.1.1. Investments Made by a Licensee
25.3.1.2. Revenues Earned by a Licensee
25.3.2. Overall Cash Flow for Licensor Companies
25.3.2.1. Investments Made by a Licensor
25.3.2.2. Revenues Earned by a Licensor
25.4. Key Analytical Outputs
25.4.1. Scenario 1: Variation of Upfront and Milestone Payments
25.4.2. Scenario 2: Variation of Upfront Payments and Sales-based Royalties
25.4.3. Scenario 3: Variation of Milestone Payments and Sales-based Royalties
26. SWOT ANALYSIS: ANTIBODY HUMANIZATION SERVICE PROVIDERS
26.1. Chapter Overview
26.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: List of Players
26.3. Antibody Humanization Service Providers: SWOT Analysis
26.3.1. Strengths
26.3.2. Weaknesses
26.3.3. Opportunities
26.3.4. Threats
27. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
27.1. Chapter Overview
27.2. Humira® (Adalimumab)
27.2.1. Drug Overview
27.2.2. Discovery Process and Method
27.2.3. Historical Sales
27.3. Keytruda® (Pembrolizumab)
27.3.1. Drug Overview
27.3.2. Discovery Process and Method
27.3.3. Historical Sales
27.4. Stelara® (Ustekinumab)
27.4.1. Drug Overview
27.4.2. Discovery Process and Method
27.4.3. Historical Sales
27.5. Dupixent® (Dupilumab)
27.5.1. Drug Overview
27.5.2. Discovery Process and Method
27.5.3. Historical Sales
27.6. Opdivo® (Nivolumab)
27.6.1. Drug Overview
27.6.2. Discovery Process and Method
27.6.3. Historical Sales
28. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY
28.1. Chapter Overview
28.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Antibody Formats
28.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
28.4. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
28.5. Rising Demand for Antibody-based Treatment Options for Non-Oncological Indications
28.6. Future Growth Opportunities in the Asia and Rest of the World
28.7. Expected Increase in Number of Collaborations and Licensing Activity
28.8 Concluding Remarks
29. CONCLUSION
30. EXECUTIVE INSIGHTS
30.1. Chapter Overview
30.2. Antibody Solutions
30.2.1. Company Snapshot
30.2.2. Interview Transcript
30.3. Adimab
30.3.1. Company Snapshot
30.3.3. Interview Transcript
30.4. ImmunoPrecise Antibodies
30.4.1. Company Snapshot
30.4.3. Interview Transcript
30.5. Anonymous
30.5.1. Anonymous, Chief Business Officer (Q3 2023)
30.6. Abveris, Acquired by Twist Biosciences
30.6.1. Company Snapshot
30.6.2. Interview Transcript
30.7. Nidus BioSciences
30.7.1. Company Snapshot
30.7.2. Interview Transcript
30.8. AvantGen
30.8.1. Company Snapshot
30.8.2. Interview Transcript
30.9. Single Cell Technology
30.9.1. Company Snapshot
30.9.2. Interview Transcript
30.10. Distributed Bio
30.10.1. Company Snapshot
30.10.2. Interview Transcript
30.11. AbCellera
30.11.1. Company Snapshot
30.11.2. Interview Transcript
30.12. AbGenics Life Sciences
30.12.1. Company Snapshot
30.12.2. Interview Transcript
30.13. CDI Laboratories
30.13.1. Company Snapshot
30.13.2. Interview Transcript
30.14. AP Biosciences
30.14.1. Company Snapshot
30.14.2. Interview Transcript
30.15. YUMAB
30.15.1. Company Snapshot
30.15.2. Interview Transcript
30.16. Antibody Solutions
30.16.1. Company Snapshot
30.16.2. Interview Transcript
30.17. Ligand Pharmaceuticals
30.17.1. Company Snapshot
30.17.2. Interview Transcript
30.18. LakePharma
30.18.1. Company Snapshot
30.18.2. Interview Transcript
31. APPENDIX 1: TABULATED DATA
32. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION
1.1. Introduction
1.2. Project Objectives
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Considerations
2.6.1. Demographics
2.6.2. Economic Factors
2.6.3. Government Regulations
2.6.4. Supply Chain
2.6.5. COVID Impact / Related Factors
2.6.6. Market Access
2.6.7. Healthcare Policies
2.6.8. Industry Consolidation
2.7. Key Market Segmentation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Trends Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Structure of Antibodies
5.3. History of Antibody Development
5.4. Antibody Isotypes
5.5. Mechanism of Action of Antibodies
5.6. Classification of Antibodies
5.6.1. Monoclonal Antibodies
5.6.2. Polyclonal Antibodies
5.6.3. Bispecific Antibodies
5.7. Applications of Antibodies
5.8. Concluding Remarks
6. ANTIBODY DISCOVERY: PROCESS AND METHODS
6.1. Chapter Overview
6.2. Antibody Discovery Process
6.2.1. Target Selection and Validation
6.2.2. Hit Generation
6.2.3. Lead Selection
6.2.4. Lead Optimization
6.2.4.1. Humanization
6.2.4.2. Affinity Maturation
6.2.4.3. Fc Engineering
6.2.5. Lead Characterization
6.2.6. Candidate Selection
6.3. Antibody Discovery Methods
6.3.1. Hybridoma Technology-based Method
6.3.2. In vitro Display Method
6.3.2.1. Phage Display
6.3.2.2. Yeast Display
6.3.2.3. Ribosomal Display
6.3.3. Transgenic Animal-based Method
6.3.4. Single B Cell-based Method
6.3.5. Advantages and Disadvantages of Existing Antibody Discovery Techniques
6.4. Evolution of Monoclonal Antibodies
6.4.1. Fully Human Monoclonal Antibodies
6.5. Concluding Remarks
7. ANTIBODY DISCOVERY SERVICE PROVIDERS: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers: List of Industry Players
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Type of Antibody Discovery Services Offered
7.2.5. Analysis by Type of Antibody Discovered
7.2.6. Analysis by Type of Antibody Discovery Method
7.2.7. Analysis by Animal Model Used
7.2.8. Analysis by Type of Antibody Discovered and Type of Antibody Discovery Method
7.2.9. Analysis by Type of Antibody Discovery Services and Location of Headquarters
7.2.10. Analysis by Application Area
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Competitiveness Analysis: Companies Grouped Grouped based on Company Size
8.4.1. Very Small Companies Offering Antibody Discovery Services
8.4.2. Small Companies Offering Antibody Discovery Services
8.4.3. Mid-sized Companies Offering Antibody Discovery Services
8.4.4. Large Companies Offering Antibody Discovery Services
8.5. Antibody Discovery Service Providers: Regional Capability
8.5.1. Antibody Discovery Service Providers based in North America
8.5.2. Antibody Discovery Service Providers based in Europe
8.5.3. Antibody Discovery Service Providers based in Asia
9. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
9.1. Chapter Overview
9.2. Antibody Discovery Service Providers in North America
9.2.1. Abwiz Bio
9.2.1.1. Company Overview
9.2.1.2. Recent Developments and Future Outlook
9.2.2. Abzena
9.2.2.1. Company Overview
9.2.2.2. Recent Developments and Future Outlook
9.2.3. Aragen Life Sciences
9.2.3.1. Company Overview
9.2.3.2. Recent Developments and Future Outlook
9.2.4. Capralogics
9.2.4.1. Company Overview
9.2.4.2. Recent Developments and Future Outlook
9.2.5. Creative Biolabs
9.2.5.1. Company Overview
9.2.5.2. Financial Information
9.2.5.3. Recent Developments and Future Outlook
9.2.6. DetaiBio
9.2.6.1. Company Overview
9.2.6.2. Recent Developments and Future Outlook
9.2.7. ImmunoPrecise Antibodies
9.2.7.1. Company Overview
9.2.7.2. Financial Information
9.2.7.3. Recent Developments and Future Outlook
9.2.8. Integral Molecular
9.2.8.1. Company Overview
9.2.8.2. Recent Developments and Future Outlook
9.2.9. Syd Labs
9.2.9.1. Company Overview
9.2.9.2. Recent Developments and Future Outlook
9.3. Antibody Discovery Service Providers in Europe
9.3.1. BIOTEM
9.3.1.1. Company Overview
9.3.1.2. Recent Developments and Future Outlook
9.3.2. FairJourney Biologics
9.3.2.1. Company Overview
9.3.2.2. Recent Developments and Future Outlook
9.3.3. Fusion Antibodies
9.3.3.1. Company Overview
9.3.3.2. Recent Developments and Future Outlook
9.3.4. Proteogenix
9.3.4.1. Company Overview
9.3.4.2. Recent Developments and Future Outlook
9.3.5. RD Biotech
9.3.5.1. Company Overview
9.3.5.2. Recent Developments and Future Outlook
9.4. Antibody Discovery Service Providers in Asia
9.4.1. ABGENEX
9.4.1.1. Company Overview
9.4.1.2. Recent Developments and Future Outlook
9.4.2. ChemPartner
9.4.2.1. Company Overview
9.4.2.2. Recent Developments and Future Outlook
9.4.3. Viva Biotech
9.4.3.1. Company Overview
9.4.3.2. Financial Information
9.4.3.3. Recent Developments and Future Outlook
9.4.4. WuXi Biologics
9.4.4.1. Company Overview
9.4.4.2. Financial Information
9.4.4.3. Recent Developments and Future Outlook
10. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET LANDSCAPE
10.1. Chapter Overview
10.2. Antibody Discovery: List of Technologies
10.2.1. Analysis by Type of Antibody Discovery Method
10.2.2. Analysis by Type of Antibody Discovered
10.2.3. Analysis by Animal Model Used
10.2.4. Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered
10.2.5. Analysis by Type of Antibody Discovery Method and Location of Headquarters
10.3. Antibody Discovery Technologies: Developer Landscape
10.3.1. Analysis by Year of Establishment
10.3.2. Analysis by Company Size
10.3.3. Analysis by Location of Headquarters
10.3.4. Most Active Players: Analysis by Number of Technologies
11. TECHNOLOGY COMPETITIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology
11.4. Antibody Discovery Technologies: Competitiveness Analysis
11.4.1. Antibody Discovery Technologies Offered by Companies based in North America
11.4.2. Antibody Discovery Technologies Offered by Companies based in Europe
11.4.3. Antibody Discovery Technologies Offered by Companies based in Asia and Rest of the World
12. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
12.1. Chapter Overview
12.2. Ablexis
12.2.1. Company Overview
12.2.2. Antibody Discovery Platform Portfolio
12.2.3. Recent Developments and Future Outlook
12.3. Creative Biolabs
12.3.1. Company Overview
12.3.2. Antibody Discovery Platform Portfolio
12.3.3. Recent Developments and Future Outlook
12.4. Genmab
12.4.1. Company Overview
12.4.2. Financial Information
12.4.3. Antibody Discovery Platform Portfolio
12.4.4. Recent Developments and Future Outlook
12.5. Harbour Biomed
12.5.1. Company Overview
12.5.2. Financial Information
12.5.3. Antibody Discovery Platform Portfolio
12.5.4. Recent Developments and Future Outlook
12.6. Immunome
12.6.1. Company Overview
12.6.2. Antibody Discovery Platform Portfolio
12.6.3. Recent Developments and Future Outlook
12.7. Isogenica
12.7.1. Company Overview
12.7.2. Antibody Discovery Platform Portfolio
12.7.3. Recent Developments and Future Outlook
12.8. Ligand Pharmaceuticals
12.8.1. Company Overview
12.8.2. Financial Information
12.8.3. Antibody Discovery Platform Portfolio
12.8.4. Recent Developments and Future Outlook
12.9. Kymab
12.9.1. Company Overview
12.9.2. Antibody Discovery Platform Portfolio
12.9.3. Recent Developments and Future Outlook
12.10. MorphoSys
12.10.1. Company Overview
12.10.2. Financial Information
12.10.3. Antibody Discovery Platform Portfolio
12.10.4. Recent Developments and Future Outlook
13. PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models
13.3. List of Partnerships and Collaborations
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Year of Partnership and Type of Partner
13.3.4. Analysis by Type of Antibody
13.3.5. Most Active Players: Analysis by Number of Partnerships
13.3.6. Most Popular Technologies: Analysis by Number of Partnerships
13.3.7. Analysis by Geography
13.3.8. Intracontinental and Intercontinental Agreements
14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. Antibody Discovery Service and Platform Providers: Funding and Investment
14.3.1. Analysis by Year of Funding
14.3.2. Analysis by Type of Funding
14.3.3. Analysis of Amount Invested by Year of Funding
14.3.4. Analysis by Year-wise Number of Funding Instances and Funding Amount
14.3.5. Most Active Players: Analysis by Number of Funding Instances
14.3.6. Most Active Players: Analysis by Amount Invested
14.3.7. Leading Investors: Analysis by Number of Funding Instances
14.3.8. Analysis by Year-wise Number of Funding Instances and Type of Player
14.3.9. Analysis by Year-wise Amount Invested and Type of Player
14.3.10. Analysis of Number of Funding Instances by Year of Establishment and Type of Player
14.3.11. Analysis by Geography
14.4. Concluding Remarks
15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
15.1. Chapter Overview
15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges
15.6. Conclusion
16. GLOBAL ANTIBODY DISCOVERY SERVICES MARKET
16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Global Antibody Discovery Services Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
16.3.1. Scenario Analysis
16.4. Key Market Segmentations
16..5. DYNAMIC DASHBOARD
17. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF SERVICE OFFERED
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Antigen Designing: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.4. Hit Generation: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.5. Lead Selection: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.6. Lead Optimization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.7. Lead Characterization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.8. Data Triangulation and Validation
18. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF ANTIBODY DISCOVERY METHOD
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Phage Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.4. Yeast Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.5. Hybridoma Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.6. Transgenic Animal based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.7. Single Cell based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.8. Other Antibody Discovery Methods: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.9. Data Triangulation and Validation
19. ANTIBODY DISCOVERY SERVICES MARKET, BY NATURE OF ANTIBODY DISCOVERED
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Humanized: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.4. Human: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.5. Chimeric: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.6. Murine: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.7. Data Triangulation and Validation
20. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF THERAPEUTIC AREAS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Oncological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.4. Immunological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.5. Infectious Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.6. Neurological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.7. Cardiovascular Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.8. Other Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.9. Data Triangulation and Validation
21. ANTIBODY DISCOVERY SERVICES MARKET, BY KEY GEOGRAPHIES
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.6. Latin America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.7. Middle East and North Africa: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.8. Rest of the World: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.9. Data Triangulation and Validation
22. GLOBAL ANTIBODY DISCOVERY TECHNOLOGIES MARKET
22.1. Chapter Overview
22.2. Assumptions and Methodology
22.3. Global Antibody Discovery Technologies Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
22.3.1. Scenario Analysis
22.4. Key Market Segmentations
22.5. Dynamic Dashboard
23. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY TYPE OF ANTIBODY DISCOVERED
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Monoclonal Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.4. Bispecific Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.5. Other Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.6. Data Triangulation and Validation
24. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY KEY GEOGRAPHIES
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.6. Data Triangulation and Validation
25. LICENSING DEAL STRUCTURE
25.1. Chapter Overview
25.2. Key Parameters
25.3. Assumptions and Methodology
25.3.1. Overall Cash Flow for Licensee Companies
25.3.1.1. Investments Made by a Licensee
25.3.1.2. Revenues Earned by a Licensee
25.3.2. Overall Cash Flow for Licensor Companies
25.3.2.1. Investments Made by a Licensor
25.3.2.2. Revenues Earned by a Licensor
25.4. Key Analytical Outputs
25.4.1. Scenario 1: Variation of Upfront and Milestone Payments
25.4.2. Scenario 2: Variation of Upfront Payments and Sales-based Royalties
25.4.3. Scenario 3: Variation of Milestone Payments and Sales-based Royalties
26. SWOT ANALYSIS: ANTIBODY HUMANIZATION SERVICE PROVIDERS
26.1. Chapter Overview
26.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: List of Players
26.3. Antibody Humanization Service Providers: SWOT Analysis
26.3.1. Strengths
26.3.2. Weaknesses
26.3.3. Opportunities
26.3.4. Threats
27. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
27.1. Chapter Overview
27.2. Humira® (Adalimumab)
27.2.1. Drug Overview
27.2.2. Discovery Process and Method
27.2.3. Historical Sales
27.3. Keytruda® (Pembrolizumab)
27.3.1. Drug Overview
27.3.2. Discovery Process and Method
27.3.3. Historical Sales
27.4. Stelara® (Ustekinumab)
27.4.1. Drug Overview
27.4.2. Discovery Process and Method
27.4.3. Historical Sales
27.5. Dupixent® (Dupilumab)
27.5.1. Drug Overview
27.5.2. Discovery Process and Method
27.5.3. Historical Sales
27.6. Opdivo® (Nivolumab)
27.6.1. Drug Overview
27.6.2. Discovery Process and Method
27.6.3. Historical Sales
28. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY
28.1. Chapter Overview
28.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Antibody Formats
28.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
28.4. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
28.5. Rising Demand for Antibody-based Treatment Options for Non-Oncological Indications
28.6. Future Growth Opportunities in the Asia and Rest of the World
28.7. Expected Increase in Number of Collaborations and Licensing Activity
28.8 Concluding Remarks
29. CONCLUSION
30. EXECUTIVE INSIGHTS
30.1. Chapter Overview
30.2. Antibody Solutions
30.2.1. Company Snapshot
30.2.2. Interview Transcript
30.3. Adimab
30.3.1. Company Snapshot
30.3.3. Interview Transcript
30.4. ImmunoPrecise Antibodies
30.4.1. Company Snapshot
30.4.3. Interview Transcript
30.5. Anonymous
30.5.1. Anonymous, Chief Business Officer (Q3 2023)
30.6. Abveris, Acquired by Twist Biosciences
30.6.1. Company Snapshot
30.6.2. Interview Transcript
30.7. Nidus BioSciences
30.7.1. Company Snapshot
30.7.2. Interview Transcript
30.8. AvantGen
30.8.1. Company Snapshot
30.8.2. Interview Transcript
30.9. Single Cell Technology
30.9.1. Company Snapshot
30.9.2. Interview Transcript
30.10. Distributed Bio
30.10.1. Company Snapshot
30.10.2. Interview Transcript
30.11. AbCellera
30.11.1. Company Snapshot
30.11.2. Interview Transcript
30.12. AbGenics Life Sciences
30.12.1. Company Snapshot
30.12.2. Interview Transcript
30.13. CDI Laboratories
30.13.1. Company Snapshot
30.13.2. Interview Transcript
30.14. AP Biosciences
30.14.1. Company Snapshot
30.14.2. Interview Transcript
30.15. YUMAB
30.15.1. Company Snapshot
30.15.2. Interview Transcript
30.16. Antibody Solutions
30.16.1. Company Snapshot
30.16.2. Interview Transcript
30.17. Ligand Pharmaceuticals
30.17.1. Company Snapshot
30.17.2. Interview Transcript
30.18. LakePharma
30.18.1. Company Snapshot
30.18.2. Interview Transcript
31. APPENDIX 1: TABULATED DATA
32. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION
